- Introduction and Disease Overview
- New and Emerging Predictive and Actionable Biomarkers for Targeted Therapies in NSCLC
- Current and Emerging Biomarkers Predicting Response to Immune-Based Therapies to Guide Precision Treatment Decisions
- Educating Patients on Their Treatment Options
- Putting It All Together: Takeaway Resources and Discussion of Available Online Resources
The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with lung cancer who have actionable biomarkers.
This program is intended for oncology nurses and other healthcare professionals who care for patients with lung cancer.
Upon completion of this activity, participants should be able to:
- Evaluate new and emerging predictive biomarkers that guide precision treatment decisions in patients with NSCLC
- Apply available clinical data and new therapeutic options for the individualized treatment of patients with actionable biomarkers
- Discuss with patients the benefits and limitations of biomarker testing and targeted therapies, along with practical considerations such as comorbidities and adherence
- Develop a proactive management plan for AEs associated with recently approved targeted agents and novel combinations
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
Designation of Credit
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.